ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P50-17 Provider Data Accuracy and Identified Lack of Claim Submissions
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 25, 2017
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2721 - 2730 လၢ 3563 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P30-16 New Prior Authorization Requirement for Lyme Disease: Diagnostic Testing and Intravenous Antibiotic Therapy
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 07, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P14-16 Addition of Lazanda ® to Existing Drug-Related Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 29, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P49-16 New Drug-Related Prior Authorization Criteria with Quantity Limit for Zavesca
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 27, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P24-16 Providers will see a change in our Prior Authorization Process for Government Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P7-16 Addition of Drugs to the Self-Administered Oral Oncology Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 27, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P5-17 Updated: Third Party Payments of Premium and/or Cost-Sharing
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P8-16 Personal Care Assistance (PCA) Service UMPI Delay Process
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P26-16 Update to Billing Guidelines for Refence and Outside Lab Services for Minnesota Health Care Programs (MHCP) Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 07, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P22-16 Pricing Order Change When Bilateral and Multiple Surgery Reduction Occur on the Same Claim
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 16, 2016